Skip to main content

Global Newsroom

CSL Behring Patient Zahra Khan, living with hereditary angioedema

Global Newsroom

Recent News Releases

Featuring releases from CSL, CSL Behring, CSL Seqirus and CSL Vifor.

Mar 27, 2023

The site will support CSL's growing R&D portfolio, accelerating the development of next-generation mRNA technology for vaccines WALTHAM, Mass., March 27, 2023 /PRNewswire/ -- Global biotechnology...

Read more news from CSL

Recent News Releases
Apr 18, 2023

Hizentra® is the first and only immune globulin (Ig) available in prefilled syringes, offering those living with Primary Immunodeficiency (PI) or Chronic Inflammatory Demyelinating Polyneuropathy...

Read more news from CSL Behring

Recent News Releases
May 21, 2023

Melbourne, Monday 22 May CSL Seqirus has today announced that construction of its new state-of-the-art manufacturing facility in Australia has reached its highest point, known as ‘topping...

Read more news from CSL Seqirus

Recent News Releases
Jun 5, 2023

Injectafer® (ferric carboxymaltose) is now the first and only intravenous (i.v.) iron replacement therapy in the U.S. indicated for improvement in exercise capacity in adult patients with...

Read more news from CSL Vifor

Read all company news releases

Media Contacts

Victoria, Australia
Phone: +61 0450 909 211

CSL Behring
North America


Asia Pacific

CSL Seqirus
EMEA and Latam
Emmanuella Dekonor
Phone: +44 7920500496

North America
Tiffany Cody
Phone: +1 908 370 1863

Asia Pacific
Hamish Walsh
Phone: 0422 424 338

CSL Plasma
United States

Follow Us Online
  • linkedin icon
  • twitter icon
  • youtube icon
  • facebook icon
  • instagram icon
Get our latest news releases in your inbox
* Required Fields